Nrx Pharmaceuticals Inc Stock Price, News & Analysis

NRx Pharmaceuticals (Nasdaq: NRXP) amended its Investigational New Drug filing for NRX-101 (D-cycloserine/lurasidone) to add use in combination with Transcranial Magnetic Stimulation (TMS) for treatment of depression, including suicidal depression, and will offer the protocol via clinical trial and Expanded Access.

Company holds >25,000 investigational doses, cites prior studies reporting 75% response/40% remission (Cole et al.) and real-world data with 87% response/72% remission at 6 weeks after a single-day TMS+DCS regimen, and says NRX-101 has composition-of-matter patents and Breakthrough Therapy designation.

NRx Pharmaceuticals (NASDAQ: NRXP) announced the FDA has received and deemed substantially complete its Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV ketamine. The FDA assigned a GDUFA goal date of July 29, 2026 for final review. NRx manufactured initial registration lots, can scale to 1 million vials per month, and seeks KETAFREE™ as a proprietary name. The company estimates the current worldwide generic ketamine market at $750 million per year and is awaiting an FDA response to an August citizen petition about Benzethonium Chloride removal. KETAFREE™ is separate from NRx’s NRX-100 program.

NRx Pharmaceuticals (NASDAQ: NRXP) will host a corporate update conference call on Tuesday, December 2, 2025 at 9:00 AM ET.

The call will cover recent clinical, regulatory, and operational developments. A live webcast will be available at https://ir.nrxpharma.com/events. Domestic participants can dial 1-800-717-1738 and international participants can dial 1-646-307-1865 to join by telephone.

NRx Pharmaceuticals (NASDAQ: NRXP) announced that Founder, Chairman, and CEO Jonathan Javitt, M.D., M.P.H. will present at NobleCon21 (Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference) on Wednesday, December 3, 2025 at 4:30 PM ET in Boca Raton, FL.

The presentation will update the company’s expanded focus and progress across investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions. The company noted it has begun generating clinical revenue and advanced drug development since NobleCon 2024.

Interested parties can register using discount code NRXPNOBLECON. A high-definition webcast will be posted the following day and archived for 90 days on the company site and on NobleCon and Channelchek.

NRx Pharmaceuticals (NASDAQ:NRXP) reported third quarter 2025 results and a corporate update on November 17, 2025. The company reported a $4.0 million loss from operations in Q3 2025 versus $3.0 million in Q3 2024, and recognized first-quarter revenue of approximately $240,000 from the September 8, 2025 Dura Medical acquisition. Cash and equivalents were $7.1 million as of September 30, 2025 ($10.3 million including a subscription receivable collected in October).

Key development highlights include an ANDA refile for preservative-free ketamine (KETAFREE™) with FDA indicating a Q2 2026 GDUFA date, Fast Track designation for NRX-100, Breakthrough status and NDA progress for NRX-101, real-world data showing doubling of TMS effect with D-cycloserine, and HOPE Therapeutics operating three revenue-generating clinics with plans for six+ by year-end. The company says operating capital is sufficient through July 2026.

NRx Pharmaceuticals (NASDAQ:NRXP) will release its third quarter 2025 financial results before the market opens on Monday, November 17, 2025.

The company will host a conference call and corporate/financial update on November 17, 2025 at 8:30 AM ET, with a live webcast available at https://ir.nrxpharma.com/events and the press release posted at https://ir.nrxpharma.com/. Participants can join by phone domestically at 1-800-717-1738 or internationally at +1-646-307-1865.

HOPE Therapeutics (NASDAQ: NRXP) began offering the Ampa ONE-D protocol for treatment‑resistant depression in Florida on Nov 10, 2025, deploying the FDA‑cleared Ampa device at clinics in Sarasota, Naples and Fort Myers with six Florida locations planned by year‑end 2025.

The ONE‑D protocol reports 87% response and 72% remission at 6 weeks in nonrandomized results when single‑day TMS is combined with physician‑prescribed D‑cycloserine and lisdexamfetamine; D‑cycloserine is also a component of investigational NRX‑101, which has Breakthrough Therapy designation and expanded access availability.

HOPE Therapeutics (NASDAQ: NRXP) announced a strategic acquisition of a stake in Cohen and Associates, LLC and the addition of Rebecca Cohen, MD as HOPE Medical Director on October 20, 2025. Cohen and Associates brings over a decade of interventional psychiatry and TMS expertise and offers ketamine, TMS, and medication management for suicidal depression, PTSD and other CNS disorders.

The company said the deal enables immediate expansion in Western Florida and Palm Beach and is expected to be accretive to HOPE Therapeutics revenue and EBITDA, while Dr. Cohen will oversee medical standards across HOPE’s Florida locations.

NRx Pharmaceuticals (NASDAQ: NRXP) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025 at 9:30 AM ET. CEO Jonathan Javitt will give a corporate update covering the company's plan to launch a low-dose D-Cycloserine (DCS) product intended to boost Transcranial Magnetic Stimulation (TMS) effectiveness for depression, citing recent medical evidence.

The presentation will detail NRx's newly acquired clinical operations in Florida and ongoing collaboration with the U.S. Department of Veterans Affairs to treat veterans with suicidal depression and PTSD. A live webcast is available to registered attendees and a replay will be posted under the company’s Events page.